Krystal Corp - רווח נקי למניה בארבעת הרבעונים האחרונים KRYS

Krystal Biotech, Inc. (KRYS) combines in-house production with external testing, although the high cost of therapy creates financial risks. On GURU.Markets, the rolling year YoY EPS growth chart visualizes these factors, where 11.40 represents the latest level value. Patent protection for unique gene delivery methods and strict FDA regulatory requirements guarantee business stability.
פילוחי מדדים פיננסיים ומדדי שוק עבור Krystal Biotech Inc (KRYS)

This indicator measures the dynamics of net earnings per share over the last twelve months relative to the same period last year, reflecting the scaling rate of the business's actual earnings. By analyzing the current EPS YoY TTM growth rate, an investor can see the results of the commercialization of gene therapy and the R&D pipeline efficiency of Krystal Biotech, Inc. (KRYS) during the implementation of innovative treatments for skin and lung diseases.